Results 151 to 160 of about 306,917 (239)

The effect of telemonitoring on quality of life in people with insulin‐treated type 2 diabetes: A secondary analysis of a randomised controlled trial

Diabetic Medicine, EarlyView.
Abstract Aims Telemonitoring in type 2 diabetes (T2D) care has demonstrated positive trends in terms of glycaemic control. However, evidence regarding its impact on patient‐reported outcomes, such as general and diabetes‐specific quality of life (QoL), remains inconclusive.
Rúni Knoph, Jannie Toft Damsgaard Nørlev, Thomas Kronborg, Peter Vestergaard, Morten Hasselstrøm Jensen, Stine Hangaard   +5 more
wiley   +1 more source

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLT2i) have proven cardiorenal benefits in type 2 diabetes and are promising as adjunct‐to‐insulin therapy in participants with type 1 diabetes (T1D). However, clinical use in T1D has been limited owing to a lack of regulatory approval and the augmented risk of diabetic ketoacidosis (DKA ...
Julia Fielden, Pam Leblanc, Chloe Parezanovic, Vikas S. Sridhar, Bruce A. Perkins, David Z. Cherney, David J. T. Campbell   +6 more
wiley   +1 more source

Efficacy and Safety of SGLT2 Inhibitors in Patients With Genetic Lipodystrophy: A Real‐Life Experience From a National Reference Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Lipodystrophy syndromes are rare diseases with metabolic and cardiovascular consequences. This study explores the metabolic and renal effects of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with genetic lipodystrophy. Patients and Methods Patients with familial partial lipodystrophy (n = 57) or congenital generalised ...
Léna Robert, Ines Belalem, Corinne Vigouroux, Hippolyte Dupuis, Marie Christine Vantyghem, Mathilde Simonson, Estelle Nobecourt, Héléna Mosbah, Sophie Beliard, Stéphanie Jellimann, Sonja Janmaat, Camille Vatier, Sophie Lamothe   +12 more
wiley   +1 more source

Uticaj metaboličke kontrole na nastanak i razvoj bubrežne lezije u šećernoj bolesti [PDF]

Vojnosanitetski Pregled, 2002
Dragović Tamara
doaj   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Diabetic Infantilism with Diabetic Nephropathy [PDF]

Proceedings of the Royal Society of Medicine, 1952
openaire   +2 more sources

Oral Butyrate Reduces Progression of Kidney Damage in an L‐NAME‐Induced Diabetic Kidney Disease Mouse Model

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Diabetic kidney disease (DKD) is one of the main causes of kidney failure worldwide. Interestingly, patients affected by DKD are characterised by a low abundance of gut bacteria producing short fatty acids including butyrate, which is suggested to play a role in the decline of renal function.
Maria Novella Nicese, Angela Koudijs, Reshma Lalai, Cristina Avramut, Rico J. E. Derks, Elena Sánchez‐López, Martin Giera, Amanda C. M. Pronk, Artemiy Kovynev, Sander Kooijman, Patrick C. N. Rensen, Roel Bijkerk, Bernard M. van den Berg, Joris I. Rotmans   +13 more
wiley   +1 more source

Person‐Reported and Continuous Glucose Monitoring (CGM) Recorded Hypoglycaemia in People With Insulin‐Treated Type 2 Diabetes and Mild to Moderate Chronic Kidney Disease; Post Hoc Analysis From the Hypo‐METRICS Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aims People with diabetes and chronic kidney disease (CKD) may be at increased risk of iatrogenic hypoglycaemia. We compared rates of sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH) in people with insulin‐treated Type 2 diabetes (T2D) with and without CKD in the Hypo‐METRICS study.
Julie M. B. Brøsen, Daniel Malmsiø, Patrick Divilly, Gilberte Martine‐Edith, Natalie Zaremba, Namam Ali, Rory J. McCrimmon, Simon Heller, Mark Evans, Bastiaan de Galan, Julia K. Mader, Eric Renard, Allan A. Vaag, Pratik Choudhary, Ulrik Pedersen‐Bjergaard, on behalf of the HypoRESOLVE Consortium, Andrew Pernet, Amy Aldridge, Marcia Henderson‐Wilson, Pernille Banck‐Petersen, Rikke Carstensen, Charlotte Hansen, Sharon Caunt, Sue Hudson, Chloe Husband, Fahad Arshad, Anne Farret, Anne‐Marie Marteil‐Oudrer, Manal Shbat, Lisa Crespy, Jenny Constanza Thibout, Anja Rasing, Jesper Walburgh Schimidt, Daniel Loewenstein, Renate Huijsmans, Pieter Drijver, Daniel Chapman, Jane Kennet, Anna Barnett, Jackie Lindsay   +39 more
wiley   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio, Michele Rossi, Amir Askarinejad, Enrico Tartaglia, Tommaso Bucci, Enrica Marrone, Dinesh K. Kalra, Claudio Ferri, Gregory Y. H. Lip   +8 more
wiley   +1 more source